End Brain Cancer Initiative teams up with Pacific Marine Biotech on glioblastoma trial

By AI, Created 11:20 AM UTC, May 20, 2026, /AGP/ – The End Brain Cancer Initiative and Pacific Marine Biotech are partnering to expand patient education and access for Immune12, an investigational treatment now enrolling people with glioblastoma in Australia. The Phase 2 trial is designed to support marketing authorization and will track feasibility, tumor response, biomarkers and quality of life.

Why it matters: - Glioblastoma is one of the most aggressive brain cancers, and the Immune12 study is aimed at generating data that could support marketing authorization in Australia. - The partnership is meant to help patients, caregivers and providers find and understand a clinical trial option for an investigational biologic. - The trial will also examine whether treatment is practical for patients, not just whether it shows signs of activity.

What happened: - The End Brain Cancer Initiative partnered with Pacific Marine Biotech to provide and promote patient disease education and expand access to Immune12. - Immune12 is a proprietary complex biologic derived from specific marine-sourced ingredients. - A Phase 2 clinical trial of Immune12 is enrolling patients with glioblastoma brain cancer. - The trial is being conducted in Australia. - Trial sites are Chris O’Brien Lifehouse in Camperdown, New South Wales, and Greenslopes Private Hospital in Greenslopes, Queensland. - The study is registered with the Australian New Zealand Clinical Trials Registry. - Dr. Janet Schloss, PhD, ND, is the chief principal investigator. - The trial plans to enroll about 60 participants.

The details: - The study will assess feasibility, including how well participants remain in the trial and follow the treatment plan. - Researchers will study blood biomarkers, including markers related to the kynurenine pathway. - The trial will measure quality of life during treatment. - MRI scans will be used throughout the study to monitor tumor response. - Tumor outcomes will be assessed using Response Assessment in Neuro-Oncology, or RANO, guidelines. - Responses may be classified as complete response, partial response, stable disease or disease progression. - Patients, caregivers and healthcare providers can pre-qualify or request more information at the trial information page. - EBCI’s Clinical Research Coordinator and Patient Navigator, Shreya Prakash, can also be reached at Shreya@EndBrainCancer.org or 425-436-8688.

Between the lines: - The trial design suggests the sponsors are looking for a mix of operational, biologic and patient-centered evidence, which can help support a later regulatory case. - EBCI’s role centers on outreach and access, while Pacific Marine Biotech is advancing the product development side. - Pacific Marine Biotech describes its broader mission as developing a safe, natural treatment solution for DIPG and glioblastoma and pursuing future FDA approval for Immune12. - The company was founded in December 2021 by Samuel Grant and Alan Temkin and is headquartered in Torrington, Connecticut. - Pacific Marine Biotech says its immediate goal is to build partnerships with U.S. healthcare institutions for clinical trials.

What’s next: - Enrollment will continue at the two Australian trial sites. - Researchers will use the Phase 2 data to inform the path toward marketing authorization in Australia. - Patients and providers interested in the study can use EBCI’s contact channels or the trial page to start the pre-qualification process.

The bottom line: - The partnership is a patient-access and trial-enrollment push around a Phase 2 glioblastoma study that could help determine whether Immune12 moves closer to broader regulatory review.